# Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

> **NCT00237159** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 284 (actual)

## Conditions studied

- Prostate Cancer Patients With Bone Metastasis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00237159
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2005-12
- **Final completion:** —
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2011-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237159, "Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00237159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*